Deals: Page 2

  • Lilly partners with Sosei to develop drugs aimed at a key family of proteins

    The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

    By Dec. 16, 2022
  • Portrait of Jeb Keiper, CEO of Nimbus Therapeutics.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics
    Q&A // Emerging biotech

    Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup

    Days after inking one of the largest deals for an unapproved drug, the CEO spoke with BioPharma Dive about the company’s unusual origins and decision to remain private — for now. 

    By Dec. 16, 2022
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK gives Wave a lift with genetic medicine deal

    A four-year agreement between the companies comes with $170 million in cash and equity for Wave, which in recent years has dealt with clinical setbacks.

    By Kristin Jensen • Dec. 14, 2022
  • A person in an office uses a virtual reality headset to examine a 3D model on a computer screen.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics

    Takeda to pay $4B for Nimbus’ TYK2 drug

    In one of the largest single-asset deals in recent history, the Japanese pharma is acquiring a medicine Nimbus claims can top Bristol Myers’ recently approved psoriasis drug Sotyktu.  

    By Dec. 13, 2022
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.

    Amgen to buy Horizon in year’s biggest biotech deal

    After outlasting rival suitors Sanofi and J&J in deal talks, Amgen agreed to a deal that values the Ireland-based maker of rare and inflammatory disease drugs at about $28 billion.

    By Updated Dec. 12, 2022
  • Two employees walk down a hallway in Gilead's Kite cell therapy unit.
    Image attribution tooltip
    Gilead Sciences Inc. / Kite Pharma

    Gilead buys into multiple myeloma cell therapy with Arcellx deal

    The company is paying Arcellx $225 million, on top of a $100 million equity investment, for rights to a CAR-T therapy that’s currently in mid-stage testing as a treatment for the blood cancer.

    By Dec. 9, 2022
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex invests in a rare disease drug and its developer

    The big biotech is paying Entrada Therapeutics $250 million upfront to grab rights to an experimental treatment for myotonic dystrophy type 1 in the latest bid to build its pipeline.  

    By Dec. 8, 2022
  • A financial graph on an abstract background
    Image attribution tooltip
    monsitj via Getty Images

    TherapeuticsMD to offload drugs to Australia’s Mayne after failed buyout

    After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal.

    By Dec. 5, 2022
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    J&J drops out of hunt for Horizon, leaving Sanofi and Amgen to bid

    The two remaining suitors said they would make cash bids if they move forward with offers, for which they must declare “firm intent” by Jan. 10 under Irish takeover rules.

    By Dec. 5, 2022
  • Pfizer, Roivant set up new company around inflammation drug

    The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing. 

    By Dec. 1, 2022
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Large pharmas probe takeover of Horizon Therapeutics

    The Dublin-headquartered drugmaker confirmed it is in "highly preliminary" talks with Amgen, J&J and Sanofi, although it cautioned no offer may ever materialize.

    By Updated Nov. 30, 2022
  • 3D rendering of T cells attacking a cancer cell.
    Image attribution tooltip
    Meletios Verras via Getty Images

    AstraZeneca reveals its cell therapy ambitions with deal for startup

    The British drugmaker will pay as much as $320 million to acquire Neogene Therapeutics, a developer of cell-based treatments for solid tumors — its first significant investment in the field.

    By Nov. 29, 2022
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.

    Merck to buy blood cancer biotech Imago for $1.35B

    The deal is Merck’s second notable acquisition in the past year and a half, part of a strategy to diversify its pipeline beyond the top-selling Keytruda.

    By Nov. 21, 2022
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip

    Regeneron teams up with CytomX to develop dual-targeting cancer drugs

    Regeneron will pay CytomX $30 million to try to create bispecific antibody drugs that are safer and have a wider reach than existing treatments.  

    By Nov. 17, 2022
  • Portrait of Joanne Kotz and Joel Barrish, two of Jnana Therapeutics' co-founders.
    Image attribution tooltip
    Permission granted by Jnana Therapeutics

    Jnana deepens ties with Roche and grabs a new round of funding

    The startup, developing drugs that target an untapped class of proteins called solute carriers, has now formed two lucrative alliances with the Swiss drugmaker since 2020.

    By Nov. 15, 2022
  • An illustration of dollar signs and small pills coming together to make one larger pill, representing a biopharma deal.
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Narcan developer to be acquired by Indivior

    The deal, which could carry a total value of roughly $145 million, is in large part focused on a nasal formulation of the opioid overdose drug nalmefene.

    By Nov. 14, 2022
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Centerview grows role as go-to adviser for biopharma dealmaking

    Over the past several years, the investment advisory firm has served as a financial adviser on biopharma acquisitions worth more than $200 billion in total, with the latest announced Monday.

    By Nov. 8, 2022
  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris

    Viatris to buy two eye drug developers in deals worth up to $750M

    The generics company is acquiring Oyster Point Pharma and the privately held Famy Life Sciences in a move aimed at creating an ophthalmology business.

    By Updated Nov. 7, 2022
  • Colorized scanning electron micrograph of a natural killer cell from a human donor.
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    Artiva cancels IPO plans and cuts a deal with Affimed

    With public offerings difficult to pull off, Artiva is focusing its energy on developing a cancer drug with the German biotech.

    By Nov. 3, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J to buy heart device maker Abiomed for $16.6B

    The deal is the biggest by J&J since its $30 billion buyout of Actelion in 2017, and comes as the company works to split its consumer health business from its pharma and medtech units. 

    By Elise Reuter • Nov. 1, 2022
  • A rendering of Astellas' planned biotech campus in South San Francisco
    Image attribution tooltip
    Courtesy of Astellas

    Astellas takes stake in gene therapy developer Taysha

    Already an investor in gene therapy, the Japanese pharma will buy 15% of the Texas biotech’s stock and gain options to two gene therapies for central nervous system disorders.

    By Oct. 24, 2022
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Myovant agrees to sell after buyer ups price

    Sumitomo Pharma, a Japanese drug company that already owns 52% of Myovant, is now offering to buy all the remaining shares for $27 apiece in a deal that values the biotech at $2.9 billion.

    By Oct. 24, 2022
  • A photo of a declining stock price.
    Image attribution tooltip
    Leonid Sorokin via Getty Images

    AGTC yields to biotech downturn with gene therapy buyout deal

    The biotech is the latest in a growing list of genetic medicine developers to sell themselves near record stock lows amid a challenging funding environment.  

    By Oct. 24, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip

    AbbVie to buy UK biotech DJS for $255M

    The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

    By Oct. 20, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J, flush with cash, says high valuations remain a dealmaking hurdle

    “We don’t have to do anything out of desperation,” said CFO Joseph Wolk on J&J’s second quarter earnings call. J&J holds $34 billion in cash and other liquid assets. 

    By Oct. 18, 2022